

Supplemental information

dCas9 fusion to computer-designed

PRC2 inhibitor reveals functional

TATA box in distal promoter region

Shiri Levy, Logeshwaran Somasundaram, Infencia Xavier Raj, Diego Ic-Mex, Ashish Phal, Sven Schmidt, Weng I. Ng, Daniel Mar, Justin Decarreau, Nicholas Moss, Ammar Alghadeer, Henrik Honkanen, Jay Sarthy, Nicholas Vitanza, R. David Hawkins, Julie Mathieu, Yuliang Wang, David Baker, Karol Bomsztyk, and Hannele Ruohola-Baker

Figure S1




Figure S1: EBdCas9 upregulates *TBX18* gene expression. Related to Figure #1

A-B. H3K27me3 ChIPseq analysis of WTC EB-Flag -Dox, EB-Flag +Dox (3 days), EBdCas9 -Dox, and EBdCas9 +Dox (3 days). **(A)** Genome-wide analysis of H3K27me3 reads mapped 2 kb around transcription start sites (TSSs). Reads were normalized via RPKM and aggregate read signal for all genes in a 2k window centered at the TSS. **(B)** Developmentally regulated genes (~1800) analysis of H3K27me3 in a 2kb window centered at the TSS. Reads were normalized via RPKM and aggregate read signal for developmental genes.

C-D. Quantification of H3K27me3 and EZH2 protein analysis. **(C)** for EBdCas9 and **(D)** for NCdCas9; ($n = 3$, SEM; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, two-tailed t test).


E-F. RNAseq analysis of EBdCas9 compared to EB-Flag. **(E)**. Volcano plot representation of bulk mRNA of differentially expressed genes (DEGs) in naïve hESC Elf1 EB22.2-FLAG 3D+Dox compared to no Dox from (Moody et al., 2017) **(F)** Volcano plot representation of bulk mRNA of differentially expressed genes (DEGs) in iPSC (WTC) EBdCas9 treated with 3D+Dox compared to no Dox. Genes with adjusted p-value < 0.05 are in blue, and genes with $\text{Log}_2\text{FC} < -1$ or $\text{Log}_2\text{FC} > 1$ and adjusted p-value < 0.05 are in red. Genes with known roles in development or pluripotency are labeled.

G. mRNA expression level of EB-GFP, NC-GFP, EBdCas9 and NCdCas9. EB-GFP, NC-GFP, EBdCas9, and NCdCas9 were all induced with Dox for 3D and harvest for EB or NC transcript expression and measured using RT-qPCR. Beta-actin was used for normalization and all samples were compared to their no Dox cell lines counterparts.


H-I. Quantifying colocalization of EED and EBdCas9 (Cas9) in fixed cells. **(H)** Representative maximum intensity projection images of nuclei in each condition. Difference of Gaussian ($\sigma_2 - \sigma_5$) was performed to remove background from images prior to max projection. Arrows in EBdCas9 +Dox/+g6*TBX18* condition demonstrates one example of colocalized spots in a nucleus. Scale bars equal 5 μm . **(I)** Scatter plot showing the percent colocalization between EED and EBdCas9 (Cas9). Each dot represents the colocalization percentage in a single cell volume slice. 10 cells were imaged for each condition in a 2-3.5 μm volume with images taken every 0.125 μm . Error bars are mean \pm SEM. ($n = 2$, SEM; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$, two-tailed t test).

Figure S2


A.



B.



C.



D.




Figure S2: EBdCas9 upregulates *TBX18* gene expression. Related to Figure #1

A. Genome browser view of H3K27me3 ChIPseq analysis for EB-GFP+Dox and EB-GFP-Dox (Moody et al., 2017) and ATACseq analysis for EB-GFP+Dox, EB-GFP-Dox, NCdCas9/g6, and EBdCas9/g6.

B. WTC KRAB-dCas9 does not activate *TBX18* or p16 after *TBX18*/g6 and p16/g1gRNAs transfection. RT-qPCR analysis of *TBX18* or p16 expression for KRABdCas9 normalized to beta-Actin and calculated as relative fold change compared to no guide (induced with Dox) of the respected cell line.

C. Genome browser view of H3K27me3 tracks for iPSC WTC 11 EBdCas9 cell line compared to H1 human embryonic stem cell line. The lower panel displays genome browser view of EZH2 and H3K27me3 tracks of *TBX18* promoter region.

D. ChIP-qPCR of induced (+Dox) EBdCas9 after 3D transfection with *TBX18* gRNAs 1-8 or no transfected cells (-g) using Cas9 Ab. Normalized to fraction input /H3.

Figure S3




Figure S3: No epigenetic remodeling for EBdCas9/ *TBX18* g7. Related to Figure #2. And, *TBX18* TSS is predominantly 600bp downstream of guide 6. Related to Figure #3

- A.** ChIP-qPCR of *TBX18* relative fold change after 3D EBdCas9 Dox induction and g7 RNA transfection. Normalized to fraction input/H3. Antibodies used for ChIP are listed above the graphs (H3K4me3, and Pol II) and the genomic region analyzed by qPCR includes *TBX18* g7 flanking region locus. n=3 biological replicates.
- B.** EBdCas9 doubling time is 16h. Cells were counted over a period of 48h and measured using nucleocounter.
- C.** ChIP-qPCR of 3D induced EBdCas9 with *TBX18* g6 RNA (+g6) transfected or not (-g) using Pol II CTD and Pol II P-Ser5 Abs and normalizing fraction input / H3 ($n = 3$, SEM; *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed t test).
- D.** *TBX18* input in FANTOM5-CAGE reveals 4 TSS peaks (p1, p2, p3, p5) measured by transcript expression (transcripts per million) among 889 human RNAseq datasets. The 3 top expressed datasets are displayed on the graph.
- E.** Depiction of *TBX18* 4 TSS peaks with respect to guide6 region.
- F.** *TBX18* CpG region snap shot from UCSC Genome Browser (GRCh36/hg36) Assembly with respect to g6 locus.
- G.** Illustration of *TBX18* TSS and CpG region. “0” denotes first Met relative to guide 6 (g6) region in bp. Small black arrows annotate the loci for qPCR amplification in F.
- H.** MedIP-qPCR of induced (+Dox) EBdCas9 after 3D transfection with *TBX18* g6 RNA (+g6) or no transfection (-g) using 5 hydroxymethylcytosine (5hmC) Ab. Normalized to fractioned input.

Figure S4


A. Quadruplex forming G-Rich Sequences (QGRS) *TBX18* Output:

```

000001 TACCACAAT ATATATATAT ATTTGTTAAT CCTAACAAA AGTCGAGTTG AAACACAAA ACAAAATGTA CAAATATATA TGTTTGGTGT CATTTAATTA
000011 AAAAGCACTG ATTTTATTTA ATTTGTTTAA AATACATCAA TGGACTCCTT AAAAGCCTGA AGTAACGATT GTAATTTGTC AACAGTAGGA CAAATATAAA
000201 CTCTACTAAA TCACAGAGAA TGGTTTCAA TGGGGAATTT TATTGCGTCT TCATACCTAT TTCATTTTGC GAAGTTTGG6 GGGGTTTTAA AGTTGCCAT
000301 ATCGTTAAAG ACGTACAGAA TGAATATCCC ATGACCTACG TTTTAAATA ACTACCACCT TTTGAAAGAA AAGGTGGCTT GGGGAAGGGG GGTGCTTTTT
000401 CTGCATTTTA TATGACGGAC TGAGCGTTAA CGTAAACATT TGCACCTCTA AAGGATTTAC ATATTTCTTA ACCTGGTATC CCCTAAGRAA AAAATCACGG
000501 AGTAAAGTTT AAATAAGCCT AAGCCATATC TGGCGCAGAC TGAGTGCAGG AACATTTTAA TGAGAAAGGA GGGGCTCGCG AATTCCTCCC AGCTTCCCAA
000601 TATCTGAGT TGTACGACA TTAAGCCATA GGGAGTGGG ACGGCAATTT ACGGACCTT GAAGAGTTC GAATTTCTA ACTGTGTGAA CGCTAGTFTT
000701 AAAGCCGGGA ACTTCCCGCT TCCACGGTCC TGGTGAAGG ACCTGGAGAC TACGGGCTTG GACTCAGCTA CGGACCTCAG AGAGACAG TTCACGCTCC
000801 GTGTGGCTGG CACATCCAG CCAACACGG GCGCTTTTCA CTCTGTTTTT TTCCGTACTT GGTAAAGGAG TGGCGCCGGG CTGGCGGAG TCGCGCCTC
000901 CTGATGTGCC GGGCGTCTG GTGATGGACA GGGAGCCGGC CTCGCCGCC CCGCTTTAT TGACACTAAT GAGCAAGTTC TTCCACCAGC TCCTCGCTC
001001 GGAAGTGTCT ACAGATCAAG GCAACAATT TCAATTACAA TCCTAATTT GTGCCACAG AGTGTTTTT ACCCATGTTA GTCTCTCTG GCGCATCAGT
001101 TGAGGCAGAC CTCGGAGCAG CAGGAGGAGG TGGAAAGGGT GGGAGCAAAG GAGTGCATCA GTGAGAGAG CCGCGAGAGA GACCCAGGA AGGAGACTTG
001201 GCGCGCGCT CGCCGGTCC TGGATCCCAA CACAAGCGA AAAGCGGAAA CGCCAAATCT GTTTTTTGGC CGCGGTCGGG AAGGGGCGAG ATCTCGGGAG
001301 GCCCCGAGAG CCTTTTAGTT TTTGGTGGG GAAGAGCGAG AGCGCGCTG TGCCCGCTG AGTGTATATG AGAGAGGGG GGGCGGGG GGGCGGGG
001401 g
  
```

B.

Transcription factor (Tf) sites (Tfscan) *TBX18* Output:




C.




Element *TBX18* Output:

| Element | Start position | Sequence | PWM score | Consensus Match | Functionally recommended scores ep2 |
|---------------------|----------------|----------|-----------|-----------------|-------------------------------------|
| TATA box | 50 | tatatgac | 0.0357 | 6 out of 8 | TATA box 0.01 |
| Mammalian Initiator | 479 | tcactoc | 0.8000 | 7 out of 7 | BRE upstream 0.05 |
| Mammalian Initiator | 894 | ccaaatc | 0.3693 | 7 out of 7 | BRE downstream 0.5 |
| Mammalian Initiator | 165 | ccatate | 0.3409 | 7 out of 7 | CAZA 0.01 |
| Mammalian Initiator | 719 | ttatgct | 0.2143 | 7 out of 7 | Chrom H3K91 0.1 |
| DPE | 748 | agacct | 0.3864 | 6 out of 6 | Mammalian Initiator 0.01 |
| Bridge 1 | 738 | cagtt | 0.0338 | 2 out of 5 | Chromatin Enhancer 0.01 |
| Bridge 2 | 750 | acct | 0.0338 | 3 out of 4 | BRCA1/2 sites 0.1 |
| Mammalian Initiator | 364 | ccaggic | 0.1705 | 6 out of 7 | MTE 0.01 |
| Mammalian Initiator | 335 | ctagtt | 0.1607 | 7 out of 7 | DPE 0.01 |
| Mammalian Initiator | 737 | tcagttg | 0.1500 | 6 out of 7 | Bridge 0.01 |
| Mammalian Initiator | 457 | ccaagcc | 0.1477 | 6 out of 7 | Human TCT 0.1 |
| Mammalian Initiator | 685 | ctaatt | 0.1393 | 7 out of 7 | Disophila TCT 0.1 |
| DPE | 714 | ccaagt | 0.0331 | 5 out of 6 | HEPE 1 0.01 |


D.



E.



F.



G.




Figure S4: *TBX18* promoter region is decorated with transcription elements. Related to Figure #4

A. Snapshot of *TBX18* 1.0kb promoter region using the QGRS mapper tool. Highlighted in yellow are the G-quadruplex elements in 5' to 3' direction.

B. Snapshot of *TBX18* (1.0kb) promoter region using transcription factor site scan using Tfsitescan tool. g6, TSS#1 and TSS#2 are labeled on the axis.

C. Snapshot of *TBX18* TATA box and other transcriptional prediction elements using ElemeNT software tool.

D. TATA box and initiator (INR) representation with respect to *TBX18* guide 5 locus using Element Navigation Tool for detection of core promoter elements.

E. RT-qPCR of EBdCas9 and *TBX18* relative fold change after 3 days Dox induction and *TBX18* g5 RNA transfection; normalized to beta-Actin and compared to no guide of each respected cell line (WT- EBdCas9 and TATA Δ #1) ($n = 3$, SEM; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, two-tailed t test).

F-G. *TBX18* (F) and Oct 4 (G) mRNA relative fold change after 3 days treatment of EPZ-6438 (5 μ M) (+) compared to untreated cells (DMS0) (-) using RT-qPCR; normalized to beta-Actin and compared to no guide of each respected cell line (WT- EBdCas9 and TATA Δ #1) ($n = 3$, SEM; * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, two-tailed t test).

Figure S5








Figure S5. EBdCas9 upregulates *p16* expression. Related to Figure #5

A. Indels of *p16* gRNAs (1-8) measuring DNA accessibility using hESC iCas9 cell line (Ferreccio et al., 2018) and Sanger sequencing. Black underlines denote gRNA region.

B-C. EBdCas9/*p16* g1 transfection results in cell proliferation reduction. **(B)** EBdCas9 brightfield after 3D *p16* g1 transfection or no transfection (-g). Scale bar is 50 μ m. **(C)** Total cell count of EBdCas9 after 3D *p16* g1 transfection or no transfection (-g) in 9cm² area field. n=3 biological replicates.

D-E. ChIP-qPCR analysis of **(D)** H3K4me3 or **(E)** H3K27ac marks after 3D transfection with *p16* g1 RNA (+g1) or no transfection (-g). Normalized to fraction Input/ H3 ; (n = 3, SEM; *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed *t* test).

Figure S6




Figure S6. EBdCas9 upregulates *p16* expression. Related to Figure #5

A. DMG transient transfection of either EBdCas9 or NCdCas9 after 3D induction with (2 μ g/ml) Dox.


B-C. Targeting EBdCas9/ g1 to p16 reduces cell viability and cell replication in DMG cells. (**D**). Cell viability assay of control (+Dox and transfected reagents) DMG or transiently transfected DMG cells with EBdCas9/g1 or NCdCas9/g1 . Times points are every 12h measured by fluorescein using Alamar Blue ($n = 3$, SEM; *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed *t* test). (**E**). EBdCas9/p16+g1 (red) EdU incorporation after 3D of transient transfection to DMG cells compared to NCdCas9/g1 (blue) and measured by FACS. Data represent mean data \pm SEM for independent experiments performed in duplicate. ($n = 2$, SEM; *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed *t* test).

D. RT-qPCR of dCas9 or p16 relative fold change after 3D Dox induction (dCas9) or p16 g1 RNA transfection (p16) of DMG cells; normalized to DMG housekeeping gene, RLP13A, and compared to control DMG no guide (+Dox) cells.


E. ChIP-qPCR of induced (+Dox) EBdCas9 and NCdCas9 after 3D transfection with p16 g1 RNA (+g1) or not transfected (-g). Normalized to fraction input /H3. Antibodies used for ChIP are listed above the graphs (Cas9, EZH2, H3K27me3 and H3K4me3); ($n = 3$, SEM; *P < 0.05, **P < 0.01, ***P < 0.001, two-tailed *t* test).

Figure S7


A.




B.




C.




D.




E.




F.




G.




H.



I.



J.



K.




Figure S7. EBdCas9 *CDX2/GATA3* promotes trophoblast trans-differentiation. Related to Figure #6

A. EPS EB-Flag and NC- Flag trophoblast differentiation time line.

B. Immunoblot of EPS EB-Flag and NC- Flag with or without Dox after 4D of trophoblast differentiation in TX media or at EPS stage.

C. Immunofluorescent imaging of 3D WTC EBdCas9 with (+) or without (-g) *CDX2* and *GATA3* g1g1 or g5g5 co-transfection. Blue-Dapi, Green-Oct4, Far red- *GATA3*; scale bar is 50 μ m.

D-E. ChIP-qPCR analysis of 3D EBdCas9 co- transfected with g5/g5 *CDX2/GATA3*. Normalized to Input/ H3 and compared to -g relative fold change. Antibodies that were used for ChIP are listed above the graphs (Cas9, EZH2, H3K27me3) and the genomic region analyzed by ChIP-qPCR includes *GATA3* g5 (**D**) and *CDX2* g5 (**E**) loci.

F. Cut and Run H3K27me3 analysis of 3 days EBdCas9 co-transfected with g5/g5 *CDX2/GATA3* or g1/g1 *CDX2/GATA3*. H3K27me3 tracks are normalized to IgG and displayed on Integrated Genome Viewer (IGV); 50kb *GATA3* window viewer. Red dots demonstrate *GATA3* TSS and exon 3 regions.

G. PCA analysis of 3 days EBdCas9 cells after co-transfection with g5/g5 *CDX2/GATA3* (green) or g1/g1 *CDX2/GATA3* (black). As controls we used EBdCas9 grown in TX media without guides (Tx-g; blue) or WTC grown in TeSR without guides (WTC-g; orange). RNAseq samples were compared to single cell RNAseq dataset from (Krendl et al., 2017) where APA (Aminopeptidase A) was used as a selective cell surface marker for trophoblast progenitor cells.

H. Immunofluorescence of EBdCas9 3D post *CDX2/GATA3* g5/g5 RNA transfection compared to no guide, and further 6 days (6D) differentiation to either EVT using 7.5mM TGF β 1 and 100ng/ml (NRG1) or ST using 2mM forskolin. Dapi- blue,ZO-1-red and (chorionic gonadotropin beta) CGB-green. Scale bar is 100 μ m.

I. WTC EBdCas9 cell line was reprogrammed to EPS, induced with Dox for 2D in TeSR and then switch to TX media (+Dox, no factors) while transfected with gRNA and harvest at 3D.

J. RT-qPCR analysis of EBdCas9 EPS cells after co-transfection with g1/g1 *CDX2/GATA3* or g5/g5 *CDX2/GATA3* compared to no guide (-g) transfection. Normalized to beta-Actin.

K. Immunofluorescent imaging of 3D EPS EBdCas9 with (+) or without (-g) *CDX2* and *GATA3* g1g1 or g5g5 co-transfection in TX media. Blue-Dapi, Green-Oct4, Far red- *GATA3*; scale bar is 50 μ m.